ASTHMA

Increase in urinary leukotriene LTE₄ levels in acute asthma: correlation with airflow limitation

S A Green, M-P Malice, W Tanaka, C A Tozzi, T F Reiss

Merck Research Laboratories, Rahway, NJ, USA

Correspondence to:
Correspondence to:
Dr S A Green
Director, Respiratory & Allergy, Merck Research Laboratories, 126 East Lincoln Avenue, RY34B-340, Rahway, NJ, USA; stuart_green{at}merck.com

Background: Leukotrienes play a key role in the pathophysiology of chronic asthma. Activation of leukotriene pathways is accompanied by rises in detectable urinary levels of leukotriene E₄ (LTE₄). The relationship between urinary LTE₄ levels and factors associated with acute asthma has not been determined.

Methods: Adults aged 15–54 years presenting with moderate to severe acute asthma were evaluated at emergency departments in 16 US sites. Forced expiratory volume in 1 second (FEV₁) was measured during the first 60 minutes after arrival and at specified times until discharge or admission. Urine samples for measurement of LTE₄ levels were obtained either on arrival at the study site and/or before discharge. Patients were seen 2 weeks later for follow up, at which time repeat FEV₁ measurements and urine samples for LTE₄ were obtained.

Results: One hundred and eighty four patients were evaluated; LTE₄ results from both the acute and follow up periods were available for analysis in 146. Urinary LTE₄ levels were increased during asthma exacerbations compared with levels obtained 2 weeks later (geometric means 111.7 and 75.6 pg/mg creatinine, respectively, mean percentage change -32.3; 95% confidence interval (CI) for the mean percentage change -39.6 to -24.3, p<0.001). The correlation between improvement in FEV₁ and decline in LTE₄ over the 2 week interval was significant (p<0.001, r = 0.43).

Conclusions: Activation of leukotriene pathways in acute asthma is correlated with the degree of airflow obstruction, and resolution of the asthma exacerbation is associated with a reduction in leukotriene levels.

Keywords: asthma; urinary leukotrienes; montelukast

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Duffield-Lillico, A. J., Boyle, J. O., Zhou, X. K., Ghosh, A., Butala, G. S., Subbaramaiah, K., Newman, R. A., Morrow, J. D., Milne, G. L., Dannenberg, A. J. (2009). Levels of Prostaglandin E Metabolite and Leukotriene E4 Are Increased in the Urine of Smokers: Evidence that Celecoxib Shunts Arachidonic Acid into the 5-Lipoxygenase Pathway. Cancer Prevention Research 2: 322-329 [Abstract] [Full Text]  
• Thompson, C., McMahon, S., Bosse, Y., Dubois, C. M., Stankova, J., Rola-Pleszczynski, M. (2008). Leukotriene D4 Up-Regulates Furin Expression through CysLT1 Receptor Signaling. Am. J. Respir. Cell Mol. Bio. 39: 227-234 [Abstract] [Full Text]  
• Thompson, C., Cloutier, A., Bosse, Y., Thivierge, M., Gouill, C. L., Larivee, P., McDonald, P. P., Stankova, J., Rola-Pleszczynski, M. (2006). CysLT1 Receptor Engagement Induces Activator Protein-1- and NF-{kappa}B-Dependent IL-8 Expression. Am. J. Respir. Cell Mol. Bio. 35: 697-704 [Abstract] [Full Text]  
• Lee, D K C, Green, S A (2004). Urinary leukotriene LTE4 levels in non-responders to antileukotriene therapy. Thorax 59: 727-727 [Full Text]  

eLetters:

Read all eLetters

Urinary leukotriene LTE₄ levels in non-responders to antileukotriene therapy

Daniel K C Lee

Thorax Online, 1 Mar 2004 [Full text]

In reply: Urinary leukotriene LTE4 levels in non-responders to antileukotriene therapy

Stuart A Green, et al.

Thorax Online, 21 Apr 2004 [Full text]